Ns Pharma, Inc.
Clinical trials sponsored by Ns Pharma, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for rare disease: can NS-229 help patients reduce steroids? Results expected Dec 2026 (estimated)
- New hope for duchenne: experimental drug targets genetic glitch Results expected Feb 2027 (estimated)
-
New hope for duchenne: experimental drug targets genetic glitch
Disease control OngoingThis study tests an experimental drug called NS-089/NCNP-02 (Brogidirsen) in 20 boys with Duchenne muscular dystrophy whose genetic mutation can be fixed by skipping exon 44. The drug is given as a weekly IV infusion and aims to help the body produce a working version of the dyst…
Phase 2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for duchenne: experimental drug aims to restore muscle protein
Disease control OngoingThis early-stage trial is testing a drug called NS-050/NCNP-03 in 20 boys with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The drug is designed to skip a faulty section of the dystrophin gene, allowing the body to produce a shorter but still functional…
Phase 1/2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare disease: can NS-229 help patients reduce steroids?
Disease control OngoingThis study tests a new medicine, NS-229, in 45 adults with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA), which causes inflammation in blood vessels. The goal is to see if NS-229 can help patients achieve remission while lowering their daily steroid d…
Phase 2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC